Lexicon Pharmaceuticals (LX31) Income Statement
Lexicon Pharmaceuticals Income Statement
Last quarter (Q2 2026), Lexicon Pharmaceuticals's total revenue was $692.00K, a decrease of 97.60% from the same quarter last year. In Q2, Lexicon Pharmaceuticals's net income was $-31.77M. See Lexicon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 49.80M | $ 31.08M | $ 1.20M | $ 139.00K | $ 298.00K | |
| $ 49.53M | $ 30.46M | $ -57.77M | $ -52.38M | $ -54.75M | |
| $ 98.44M | $ 227.58M | $ 113.98M | $ 48.38M | $ 32.34M | |
| Depreciation and Amortization | $ 621.00K | $ 534.00K | $ 554.00K | $ 427.00K | $ 292.00K |
| $ -41.38M | $ -184.29M | $ -169.76M | $ -100.03M | $ -86.66M | |
| $ -48.91M | $ -197.12M | $ -171.75M | $ -100.76M | $ -87.09M | |
| $ -1.43M | $ -3.29M | $ -5.37M | $ -1.18M | $ -668.00K | |
| $ -50.34M | $ -200.40M | $ -177.12M | $ -101.94M | $ -87.76M | |
| $ -50.34M | $ -200.40M | $ -177.12M | $ -101.94M | $ -87.76M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.14 | $ -0.63 | $ -0.80 | $ -0.62 | $ -0.61 |
| Diluted EPS | $ -0.14 | $ -0.63 | $ -0.80 | $ -0.62 | $ -0.61 |
| Weighted Average Shares Outstanding | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M |
| Weighted Average Shares Outstanding (Diluted) | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M |
Currency in USD